cyrilzakka/clinical-trials huggingface dataset:
MyNewOptions: An Online Study of Reproductive Life Planning and Contraceptive Action Planning

The purpose of this web-based study is to determine whether reproductive life planning (RLP), with or without contraceptive action planning (RLP+), will result in reduced risk of unintended pregnancy when compared to an information-only control group.

Most US families want 2 children, resulting in the average woman spending 3 decades of her life trying to avoid pregnancy. However, most women have at least one unintended pregnancy, resulting in 1.5 million abortions and 1.7 million unintended births annually. Women and couples try to avoid unintended pregnancy for a range of personal, social, and economic reasons, but also due to the increased physical and mental health effects for children that result from unintended pregnancy. Healthcare reform now requires that private health insurance companies cover all FDA-approved contraceptive methods with no copays or deductibles to the patient, creating a great opportunity for women with health insurance to get contraceptive methods they previously could not afford. In this study, women with health insurance will be randomly assigned to one of three groups: (1) Reproductive Life Planning (RLP)-women will complete a reproductive life plan that guides them to think about if and when they would want any future pregnancies, and to determine what contraceptive method(s) are best suited to them; (2) Reproductive Life Planning Plus (RLP+) which additionally includes "if-then planning," where women determine what they will do when they encounter difficult situations that make it difficult to use their contraceptive method perfectly; or (3) an information-only control group. The online format of the study allows for the potential of wide dissemination. The RLP and RLP+ interventions are expected to result in greater likelihood of contraceptive use, continuity of contraceptive use, and contraceptive adherence, and thus reduce overall risk of unintended pregnancy.

Eligibility Criteria:
Inclusion Criteria:

* not currently pregnant
* sexually active with a male partner in the past 6 months OR anticipate being sexually active with a male partner in the next 6 months
* does not intend pregnancy in the next 12 months
* has Internet access and email address

Exclusion Criteria:

* tubal sterilization
* hysterectomy
* partner with vasectomy
Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya

In this study, the investigators aim to evaluate the indirect revascularization outcomes of a new combination therapy of multiple burrhole procedure with promotion of arteriogenesis by intravenous (IV) erythropoietin (EPO) pretreatment on Moyamoya patients with acute neurological presentation, and outline the clinical and vascular factors associated with revascularization through the burrholes.

This is a investigator led, single-center, single arm, interventional trial in prospective Moyamoya disease (MMD) and Moyamoya syndrome (MMS) registry. MMD or MMS patients with acute neurological presentation such as ischemic stroke or transient ischemic attack are eligible.

After inclusion, initial evaluation including transfemoral angiography is performed. A 3 day pre-procedure IV erythropoietin (120000 international units\[IU\] #3) is given for promotion of arteriogenesis, than multiple burrhole procedure is performed. Arteriogenesis is evaluated by 6 month transfemoral angiography.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥16 years
* Acute neurological presentation with recurrent transient ischemic attacks (TIA) or cerebral infarction within 30 days of symptom onset
* Angiographic findings compatible with the diagnostic criteria for MMD or MMS (unilateral findings, bilateral distal internal carotid artery involvement without Moyamoya vessels, or presence of other causative factors)
* Significant decrease in basal perfusion and reservoir capacity on brain perfusion CT or Brain single photon emission computed tomography with acetazolamide (Diamox®) challenge (D-SPECT)

Exclusion Criteria:

* Definite presence of transdural collateral flow on cerebral angiography.
* Sufficient perfusion status via Willisian, leptomeningeal, or other collateral systems, as evaluated by multimodal imaging methods.
* \> 30 days after symptom onset
Detection of Cannabis Impairment With an Eye Tracker

Cannabis is one of the widely used psychoactive substances in the world. With increasing legalization, the prevalence of driving under the influence of cannabis will undoubtedly rise. At present, roadside detection of cannabis intoxication is largely dependent on drug recognition experts who rely on changes in eye movements when impaired. In this regard, use of eye trackers can help to detect impairment in drivers. The purpose of the present study is to determine the feasibility of the use of eye trackers in detecting impairment in participants who smoked a cannabis cigarette.

Participants will attend one study session after determination of eligibility. During this session, they will smoke a cannabis cigarette with 12.5% THC prior to driving a simulator. Driving will be assessed prior to smoking cannabis and at 7 time points after smoking cannabis. Eye tracking measures will also be taken while driving after smoking cannabis. Blood will be drawn for determination of levels of the psychoactive substance THC and its metabolites. Saliva tests, urine tests and subjective tests will also be performed at various times points after smoking cannabis.

Eligibility Criteria:
Inclusion Criteria:

* Weekly use of cannabis (1 to 4 days per week) confirmed by urine point-of-care testing;
* 19-26 years of age;
* holds a class G or G2 Ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months;
* Willing to abstain from using alcohol for 48 hours and cannabis for 72 hours prior to the study session;
* Willing to abstain from all other drugs not prescribed for medical purposes for the duration of the study;
* Provides written and informed consent.

Exclusion Criteria:

* Urine toxicology screens negative for cannabis upon eligibility assessment;
* Diagnosis of severe medical or psychiatric conditions;
* Females: Pregnancy or breastfeeding;
* Meets criteria for Alcohol or Substance Dependence (current or lifetime) (DSM-IV);
* Is a regular user of medications that affect brain function (i.e., antidepressants, benzodiazepines, stimulants);
* First-degree relative diagnosed with schizophrenia.
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy

Robotic-assisted laparoscopic prostatectomy (RALP) is the gold standard surgical technique in prostate surgery. Many Robotic-laparoscopic surgical techniques also require the intraoperative deep Trendelenburg position and intravenous fluid restriction during surgery. However, the possible side effects of the deep Trendelenburg's position and the fluid restriction on the cardiovascular and renal systems during surgery are unknown. Although the Trendelenburg position is a life-saving maneuver in hypovolemic patients, it also carries undesirable risks. Long console time may contribute to the development of acute kidney injury (AKI) by prolonging the Trendelenburg time and the fluid-restricted time. In this study, investigators aimed to demonstrate the effect of console time on the development of AKI. Investigators also aimed to determine the hemodynamic risk factors that cause the development of AKI in patients monitored with the pressure Recording Analytical Method (PRAM).

Although open surgery has been used for a long time in the treatment of prostate diseases, robotic-assisted laparoscopic prostatectomy (RALP) has become more common in the last 20 years. The excellence in results has made the use of the robot the gold standard in prostate surgery. However, the presence of two critical factors during RALP surgery still bothers clinicians. The first of these is severe fluid restriction and the other is the deep Trendelenburg position and pneumoperitoneum. The prolongation of the robotic console time also causes the prolongation of fluid restriction and Trendelenburg time. This combination may cause significant pathophysiological changes in both the renal and cardiac systems and may lead to postoperative acute renal injury (AKI). AKI is a serious clinical complication with increasing incidence and is associated with adverse short-term and long-term outcomes worldwide, resulting in a large healthcare burden. Intraoperative advanced monitoring techniques can contribute to the prevention of renal damage that may occur by providing early recognition of these pathophysiological changes occurring in the renal and cardiac systems.

The aim of our study was to determine the effect of console duration on the incidence of AKI after RALP which was managed using intraoperative advanced monitoring techniques (pressure recording analytical method-PRAM). In addition, this study aimed to evaluate the ability of changes in hemodynamic parameters to predict the development of AKI in RALP patients who underwent restrictive fluid therapy.

Eligibility Criteria:
Inclusion Criteria:

* Patients with American Society Of Anesthesiology physical status 1-3
* Underwent Robotic-assisted laparoscopic prostatectomy
* Underwent restrictive fluid therapy during the console period

Exclusion Criteria:

* Under 18 years of age
* Arrhythmia (atrial fibrillation, frequent premature beat)
* History of myocardial infarction in the last 3 months
* Heart failure
* Severe pre-existing lung disease
* Severe valvular heart disease
* Chronic renal disease on dialysis,
Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine

To develop and apply quantitative methods by which to measure and characterize blood transfusion practice in specific diagnoses and procedures; to open scientific communication about transfusion practice within and across institutions; and to develop simpler methods for estimating annual national blood collections and transfusions.

DESIGN NARRATIVE:

The study was a subproject within a Specialized Centers of Research (SCOR) in Transfusion Medicine. The experimental design was based on the study and analysis of several unique sets of data. One set consisted of abstracted patient data including ICD-9-CM diagnosis and procedure, DRG and red cell units transfused, from a constant set 100 of United States hospitals for the years 1980,82,84,86, to which a new set of data was added for the year 1989. A similar set of data were gathered from eight cooperating teaching hospitals over the first four years of the grant term; this set included data for transfusions of all blood components, autologous units and factor preparations. A third data base contained the data for four United States surveys conducted in 1982,84,86,87; and was expanded to include 1990 and 92. Using these data, four main tasks were addressed. A Pan-DRG red cell transfusion study was conducted to ascertain red cell use across all DRGs and ICD-9-CM codes. Extensive efforts were devoted to developing new methods to characterize transfusion practice. A series of studies were devoted to characterizing transfusions of all blood components in a selected number of ICD-9-CM classes. The purpose of the fourth task was to develop simpler and more rapid alternative methods for producing national estimates of transfusion activity; as part of this task,new surveys were conducted for 1990 and 92.

Among the questions studied were: Was it possible to identify distinctive attributes of the patients who, though operated, did not require a transfusion or who required a large volume of blood? Were transfusions of non-red cell components related to use of red cells? Could transfusion frequency diagnosis for all blood products be used as a measure of transfusion practice? Did longitudinal comparisons of transfusions over the 9-year interval, 1980-1989, reveal significant trends? Was it possible to discriminate quantitatively between transfusion practices in different hospitals or set of hospitals, or at different times? What was the effect of autologous blood programs in transfusion practice? What was the contribution of comorbid conditions on red cell and component transfusion patterns.?

The dollars for the subproject were approximately 25 percent of total dollars spent each year for the Center.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility Criteria:
No eligibility criteria
Non-Invasive Jugular Venous Blood Volume Assessment (BVI)

The purpose of this study is to evaluate the ability of the Mespere Blood Volume Index (BVI) device to calculate the blood volume in the jugular veins by comparing the measurements from the device to volumetric measurements obtained with ultrasound.


Eligibility Criteria:
Inclusion Criteria:

1. 18 years of age or greater
2. English-speaking
3. No known medical conditions requiring treatment by a physician

Exclusion Criteria:

1. Substantial amount of neck hair preventing adhesion of the neck patch of the BVI
2. History of congenital heart disease
3. History of thoracic, neck or brain surgery
4. Inability to lay supine at 30 degrees incline or 60 degrees incline for the duration of the study measurements
5. Pregnancy
Feasibility Study on the Effect of Complementary Methods as Supportive Interventions for Parents of Children With Cancer

The purpose of this study is to determine whether Guided Imagery and Progressive Muscle relaxation are effective as stress reducing techniques in parents of hospitalized children with cancer.

Having a children with cancer can be a source of stress for parents during hospitalization. The stress experienced by the parents can negatively influence their functionality, daily activities, psychological state and also their physical condition. The studies in the literature have mainly focused on the child rather than the parent, and studies specifically for guided imagery are scarce. Since the parents are often neglected by the healthcare professionals during the stress evoking period of hospitalization, this study will test the effectiveness of complementary methods in improving the psychological state of the parents.

Eligibility Criteria:
Inclusion Criteria:

* willingness to participate
* having a child with childhood cancer been hospitalized for 4 weeks
* have a child (0-18) of age with childhood cancer
* able to speak and write Greek fluently
* no previous experience with CAM techniques

Exclusion Criteria:

* receiving drug therapy for stress
* using another CAM technique during the study

  * parents of children receiving palliative care
Evaluation of a Full Face Mask and Headgear for the Treatment of Obstructive Sleep Apnea

Currently Fisher \& Paykel Healthcare (FPH) is developing a new full face mask. The objective of this clinical investigation is to evaluate the usability and acceptance of the investigative mask, the effectiveness of the seal and headgear.

The participant will be randomised to use either full face mask prototype 1 or 2 as according to the randomization log for 7 ± 3 days in home. The participant will then crossover to the other full face mask prototype to use in home for 7 ± 3 days. Neither the investigators or the participants will be blinded to the study.


Eligibility Criteria:
Inclusion Criteria:

* AHI ≥ 5 from the diagnostic night
* ≥ 18 years of age
* Either prescribed APAP or CPAP or Bi level for OSA
* Existing full face users

Exclusion Criteria:

* Inability to give informed consent
* Participant intolerance to PAP
* Anatomical or physiological conditions making PAP therapy inappropriate
* Current diagnosis of respiratory disease or CO2 retention
* Pregnant or think they may be pregnant
Contemporary Clinical Management Of Acute Pulmonary Embolism

Acute pulmonary embolism is a potentially life-threatening disease with short-term mortality ranges from less than 1% to more than 30% during the hospital stay. Recent guidelines recommend to tailor diagnosis hospitalization and acute treatment based on the estimated risk for short-term Death.

The assessment of the contemporary clinical management of patients with acute pulmonary embolism across different specialties would be of crucial value.

This is a prospective, non-interventional, multicenter study in patients with acute pulmonary embolism admitted to Cardiology, Emergency and Internal Medicine Departments in Italy.

The aim of the study is to assess contemporary management strategies in patients with acute pulmonary embolism in terms of diagnosis, risk stratification, hospitalization and treatment in Italy and assess

1. their association with in-hospital and 30-day mortality and
2. their adherence to current guidelines of the European Society of Cardiology (ESC).

Eligibility Criteria:
Inclusion Criteria:

* Patients with acute, symptomatic acute pulmonary embolism
* Age ≥ 18 years
* Informed consent

Exclusion Criteria:

* refusal of informed consent
* participation in controlled trials on the management of patients with acute pulmonary embolism
Prospective Registry of Outcomes and Management of Acute Ischaemic Syndromes

This is a multi-centre UK study designed to evaluate if an educational intervention programme delivered to health care professionals can improve the use of evidence based treatments in the management of patients admitted to hospital with non-ST elevation Acute Coronary Syndrome. A total of 38 centres participated, half received the educational intervention. Patients were followed to hospital discharge. Patients were followed up at 6 months. Longer term follow up through the Office Of National Statistics will be performed.

This is a multi-centre UK study designed to evaluate if an educational intervention programme delivered to health care professionals can improve the use of evidence based treatments in the management of patients admitted to hospital with non-ST elevation Acute Coronary Syndrome. A total of 38 centres participated. A cluster randomised method was used and half of centres received the educational intervention. Patients were followed to hospital discharge. Patients were followed up at 6 months and longer term follow up for mortality will be performed through the national databases.

Eligibility Criteria:
Inclusion Criteria:All patients admitted to the hospital (either through casualty or directly to the wards), with a good clinical history of an acute coronary syndrome with one or more of the following:

1. Ischaemic changes on the admission ECG (including patients with bundle branch block)
2. Elevated Troponin or cardiac enzymes on admission
3. Normal ECGs but with evidence of pre-existing coronary artery disease i.e., evidence of a prior history of MI, coronary revascularisation, coronary angiography demonstrating the presence of significant coronary stenosis or a stress test demonstrating ischaemia (treadmill, echo or nuclear scan)

Written informed consent

Exclusion Criteria:

1. Patients with persistent ST elevation \>1mm in two or more contiguous leads on the ECG.
2. Patients treated with thrombolytic therapy, or for whom thrombolytic therapy was considered on admission.
Berries, Bugs, and the Blues

This study aims to investigate the impact of daily freeze-dried blueberry powder consumption on the gut microbiota, fecal short chain fatty acids, and depressive symptom severity in 40older, sedentary adults with depressive symptoms.

This study is an ancillary project to a currently funded randomized, placebo-controlled 12-week intervention in older, sedentary adults with depressive symptoms (IRB# Pro00064749). This specific project proposes distinct aims to the trial by gathering preliminary data on the synergistic impact of dietary fiber and anthocyanins (via freeze-dried blueberry powder) on the gut-microbiota, gut-derived metabolites, and depressive symptoms in older adults.

Participants will then be randomized to consume either 48 g of freeze-dried blueberry powder (\~600 mg of anthocyanins and \~8 g of fiber) or 48 g of a nutritionally matched placebo powder (devoid of anthocyanins and fiber) each day for a total of 12 weeks.

At baseline, participants will be undergo assessments for depressive symptom severity and provide a fecal sample for gut microbiota and short chain fatty acid measurement. After 4, 8, and 12 weeks of consuming the powder there will be study visits that assess depressive symptom severity. Additionally, a final fecal sample will be taken after 12 weeks of the intervention.

Eligibility Criteria:
Inclusion Criteria:

* Men and women aged ≥65 years
* Self-reporting ≥ 8 hours of sitting per/day (e.g., sedentary behavior)
* Depressive symptoms (defined as ≥4 and \<16 points on the center for epidemiological studies depression-scale

Exclusion Criteria:

* Unwilling to follow the study protocol
* A median daily step count \>7,500 steps per day (as measured by the ActiGraph), or per discretion of the PI
* Cognitive impairment (defined as Montreal Cognitive Assessment, MoCA \<22 points)
* Self-reporting a history of inflammatory bowel disease/syndrome, major depression, bipolar, schizophrenia, or other psychotic disorders, or per discretion of the PI
* Self-reporting type 1 or type 2 diabetes
* Allergic to intervention or control products
* Recent use (within the last 3 months) of antibiotics, or per discretion of the PI
* Recent use (within the last 3 months) of pro-biotics, or per discretion of the PI
* Current substance use disorder (Drug Abuse Screening Test, DAST-10\>2 points)
* Current alcohol use disorder (Alcohol Use Disorders Identification Test - Consumption, AUDIT-C≥4 points)
* Unstable anti-depressant use (e.g., change in medication within last 3-6 months), or per discretion of the PI
* Current homicidal or suicidal ideation (assessed via the P4 Suicidality Screener)
* Current psychosis (via the Psychosis and Hallucinations Questionnaire, PHQ\>12 points)
* Manic symptoms (assessed by the Mood Disorder Questionnaire, MDQ \>5 points)
Dexmedetomidine vs. Midazolam Sedation for Endobronchial Ultrasound

The randomized controlled trial will compare efficacy and safety of dexmedetomidine to midazolam for sedation during endobronchial ultrasound

Benzodiazepines, opioids, and propofol are currently used alone or in combination for achieving sedation during endobronchial ultrasound and other bronchoscopic procedures. However, all these agents carry a risk of respiratory depression. Dexmedetomidine, a highly selective adrenergic alpha-2 agonist, has sedative and analgesic properties but does not cause respiratory depression. This study aims to compare efficacy and safety of dexmedetomidine as a sedative to midazolam in patients with hilar/mediastinal lymphadenopathy undergoing convex-probe endobronchial ultrasonography on day care basis. Patients will be randomized to receive either dexmedetomidine plus fentanyl or midazolam plus fentanyl prior to procedure, followed by dexmedetomidine or saline infusion respectively during the procedure. Ramsay sedation score of two will be targeted, failing which patients in both groups will receive midazolam bolus on as-needed basis. Bronchoscopist will remain blinded to group allocation. Patients will be monitored for sedation, oxygenation and hemodynamic parameters throughout. Need for additional midazolam, sedative efficacy, frequency of adverse respiratory and hemodynamic events, and bronchoscopist and patient satisfaction with the procedure will be compared between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or more
* American Society of Anesthesiologists physical status I or II
* Presence of hilar and/or mediastinal lymph nodes on thoracic CT scan

Exclusion Criteria:

* Known allergy to dexmedetomidine or midazolam or fentanyl
* Documented coagulopathy
* Pregnancy
* Hemodynamic instability (hypotension, arrhythmia, recent acute coronary event)
* Neuropsychiatric illness
* History of previous endobronchial ultrasound procedure
* Refusal to provide consent